Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Slashes Loss, Sees Slight Gain in Revenues

NEW YORK, Aug. 13 (GenomeWeb News) - DeCode Genetics slashed its net loss nearly by half for the second quarter and reported narrow revenue growth today.

 

The company had revenue of $10.5 million for the second quarter, ending June 30, compared to $9.4 million for the year-ago quarter. Net loss was $10.2 milllion, compared to $19.7 million for the same period in 2002.

 

The firm cut its research and development expenditures to $16.7 million for the quarter, compared to $24 million for the second quarter, 2002.

 

The Iceland-based firm said it has $77 million in cash and cash equivalents at the close of the quarter on June 30.

 

The company said it had $12.7 million in deferred revenue, which will be recognized in future reporting periods.

 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.